Hepion Pharmaceuticals, Inc. (HEPA): R&D Expense
$445.5K
Year ended 2025-12-31
$120.9K
Trailing 12 months to 2026-06-30
-76.3%
3-year compound annual growth
-48.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $445.5K | -96.2% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $11.85M | -66.8% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $35.64M | +7.1% | 2025-04-08, From 2023-01-01 |
| 2022-12-31 | $33.27M | +63.1% | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | $20.40M | +70.0% | 2023-04-10, From 2021-01-01 |
| 2020-12-31 | $12.00M | +276.8% | 2022-04-08, From 2020-01-01 |
| 2019-12-31 | $3.18M | -58.1% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $7.59M | -43.2% | 2020-05-14, From 2018-01-01 |
| 2017-12-31 | $13.37M | n/a | 2019-03-14, From 2017-01-01 |
| No annual figure between 2016-06-30 and 2017-12-31. | |||
| 2016-06-30 | $15.02M | +78.7% | 2017-09-28, From 2015-07-01 |
| 2015-06-30 | $8.40M | n/m | 2016-09-28, From 2014-07-01 |
| 2014-06-30 | $314.2K | n/a | 2015-09-25, From 2013-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | 2025-12-31 | $445.5K | -96.2% |
| InMed Pharmaceuticals Inc. (INM) | 2026-06-30 | $3.03M | +7.3% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.36M | +276.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Palatin Technologies Inc (PTN) | 2025-06-30 | $14.90M | -33.5% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $5.42M | -9.5% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
Compare HEPA, INM, TCRT, ATXI side by side · Screen every company in Pharmaceutical Preparations ↗